| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | - | - | - | 9.836 | 6.191 | 10.320 | 12.234 | 26.168 | 35.509 |
| Total Income - EUR | - | - | - | - | 9.836 | 8.192 | 10.320 | 12.234 | 26.168 | 35.509 |
| Total Expenses - EUR | - | - | - | - | 2.898 | 2.220 | 3.054 | 2.317 | 6.074 | 7.115 |
| Gross Profit/Loss - EUR | - | - | - | - | 6.938 | 5.972 | 7.267 | 9.916 | 20.094 | 28.394 |
| Net Profit/Loss - EUR | - | - | - | - | 6.644 | 5.786 | 7.002 | 9.568 | 16.943 | 24.532 |
| Employees | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 |
Check the financial reports for the company - Thyroins S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | - | - | - | 580 | 1.163 | 1.375 | 563 | 269 | 196 |
| Current Assets | - | - | - | - | 6.596 | 11.133 | 13.410 | 13.639 | 21.240 | 45.091 |
| Inventories | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | - | - | - | - | 0 | 4.460 | 10.709 | 10.984 | 11.925 | 39.105 |
| Cash | - | - | - | - | 6.596 | 6.674 | 2.701 | 2.656 | 9.315 | 5.986 |
| Shareholders Funds | - | - | - | - | 6.578 | 12.239 | 14.698 | 13.415 | 20.560 | 44.978 |
| Social Capital | - | - | - | - | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | - | - | - | - | 598 | 57 | 88 | 787 | 949 | 309 |
| Income in Advance | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "8622 - 8622" | |||||||||
| CAEN Financial Year |
8622
|
|||||||||
Comments - Thyroins S.r.l.